Retatrutide hits 28% weight loss in Phase 3
chamath.substack.com · 820 words · saved by 1 readers
A summary of the interesting content that I consumed this past week…
What I Read This Week: a summary of the content that I consumed this past week… Caught My Eye… 1) Retatrutide hits 28% weight loss in Phase 3 On May 21, Eli Lilly released Phase 3 results for retatrutide from the 2,339-patient TRIUMPH-1 obesity trial. On average, with a 12mg dose, participants lost 28.3% of body weight (70.3 lbs) over 80 weeks against 2.2% on placebo (5.5 lbs). 65.3% dropped below the obesity cutoff of a 30 BMI, and 45.3% of the cohort hit at least 30% weight loss. This is comparable to bariatric surgery, which removes part of the stomach to help patients eat less and…
related reading
- Semaglutide & Its Friendspanpharmacon.substack.com
- The Promise and Impact of the Next Generation of Weight Loss Drugsmetaculus.com
- Semaglutidonomicsastralcodexten.com
- Why Does Ozempic Cure All Diseases?astralcodexten.com
- Articles — Asimov Presspress.asimov.com
- The Worst Argument Against Ozempic - Cremieux Recueilcremieux.xyz
- Join Delilah: Personalized Weight Management for Womenjoindelilah.com
- How ‘miracle’ weight-loss drugs will change the worldnature.com
- Semaglutide - Wikipediaen.wikipedia.org
- If GLP-1 Drugs Are Good For Everything, Should We All Be on Them?derekthompson.org
- GLP-1 drug use cuts grocery spending by 6%, study findsfooddive.com
- The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com